CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma

Clinical trial NCT02027935 · COMPLETED

Trial details

NCT number: NCT02027935
Sponsor: M.D. Anderson Cancer Center
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Metastatic Melanoma Stage IV Cutaneous Melanoma AJCC v6 and v7

Start date: 2015-01-22
Primary completion: 2024-04-12
Enrollment: 16

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.